These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

838 related items for PubMed ID: 32684339

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors.
    Li S, Siriwon N, Zhang X, Yang S, Jin T, He F, Kim YJ, Mac J, Lu Z, Wang S, Han X, Wang P.
    Clin Cancer Res; 2017 Nov 15; 23(22):6982-6992. PubMed ID: 28912137
    [Abstract] [Full Text] [Related]

  • 3. CD19-specific CAR T Cells that Express a PD-1/CD28 Chimeric Switch-Receptor are Effective in Patients with PD-L1-positive B-Cell Lymphoma.
    Liu H, Lei W, Zhang C, Yang C, Wei J, Guo Q, Guo X, Chen Z, Lu Y, Young KH, Lu Z, Qian W.
    Clin Cancer Res; 2021 Jan 15; 27(2):473-484. PubMed ID: 33028589
    [Abstract] [Full Text] [Related]

  • 4. ShRNA-mediated silencing of PD-1 augments the efficacy of chimeric antigen receptor T cells on subcutaneous prostate and leukemia xenograft.
    Zhou JE, Yu J, Wang Y, Wang H, Wang J, Wang Y, Yu L, Yan Z.
    Biomed Pharmacother; 2021 May 15; 137():111339. PubMed ID: 33550044
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells.
    Rupp LJ, Schumann K, Roybal KT, Gate RE, Ye CJ, Lim WA, Marson A.
    Sci Rep; 2017 Apr 07; 7(1):737. PubMed ID: 28389661
    [Abstract] [Full Text] [Related]

  • 7. Dual-function chimeric antigen receptor T cells targeting c-Met and PD-1 exhibit potent anti-tumor efficacy in solid tumors.
    Yuan X, Sun Z, Yuan Q, Hou W, Liang Q, Wang Y, Mo W, Wang H, Yu M.
    Invest New Drugs; 2021 Feb 07; 39(1):34-51. PubMed ID: 32772342
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Engineering a HER2-CAR-NK Cell Secreting Soluble Programmed Cell Death Protein with Superior Antitumor Efficacy.
    Xia W, Chen J, Hou W, Chen J, Xiong Y, Li H, Qi X, Xu H, Xie Z, Li M, Zhang X, Li J.
    Int J Mol Sci; 2023 Apr 06; 24(7):. PubMed ID: 37047817
    [Abstract] [Full Text] [Related]

  • 10. PD-1-CD28-enhanced receptor and CD19 CAR-modified tumor-infiltrating T lymphocytes produce potential anti-tumor ability in solid tumors.
    Chen X, Zhao X, Mou X, Zhao J, Zhang Z, Zhang X, Huang J, Liu Y, Wang F, Zhang M, Wang L, Gu W, Zhang Y.
    Biomed Pharmacother; 2024 Jun 06; 175():116800. PubMed ID: 38788547
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells.
    Lee MY, Robbins Y, Sievers C, Friedman J, Abdul Sater H, Clavijo PE, Judd N, Tsong E, Silvin C, Soon-Shiong P, Padget MR, Schlom J, Hodge J, Hinrichs C, Allen C.
    J Immunother Cancer; 2021 Mar 06; 9(3):. PubMed ID: 33741731
    [Abstract] [Full Text] [Related]

  • 13. CAR affinity modulates the sensitivity of CAR-T cells to PD-1/PD-L1-mediated inhibition.
    Andreu-Saumell I, Rodriguez-Garcia A, Mühlgrabner V, Gimenez-Alejandre M, Marzal B, Castellsagué J, Brasó-Maristany F, Calderon H, Angelats L, Colell S, Nuding M, Soria-Castellano M, Barbao P, Prat A, Urbano-Ispizua A, Huppa JB, Guedan S.
    Nat Commun; 2024 Apr 26; 15(1):3552. PubMed ID: 38670972
    [Abstract] [Full Text] [Related]

  • 14. Improved survival of chimeric antigen receptor-engineered T (CAR-T) and tumor-specific T cells caused by anti-programmed cell death protein 1 single-chain variable fragment-producing CAR-T cells.
    Nakajima M, Sakoda Y, Adachi K, Nagano H, Tamada K.
    Cancer Sci; 2019 Oct 26; 110(10):3079-3088. PubMed ID: 31432594
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Enhanced antitumor efficacy, proliferative capacity, and alleviation of T cell exhaustion by fifth-generation chimeric antigen receptor T cells targeting B cell maturation antigen in multiple myeloma.
    Yuti P, Sawasdee N, Natungnuy K, Rujirachaivej P, Luangwattananun P, Sujjitjoon J, Yenchitsomanus PT.
    Biomed Pharmacother; 2023 Dec 26; 168():115691. PubMed ID: 37844355
    [Abstract] [Full Text] [Related]

  • 20. Expression of VISTA regulated via IFN-γ governs endogenous T-cell function and exhibits correlation with the efficacy of CD19 CAR-T cell treated B-malignant mice.
    Tang D, Zhao L, Yan F, Ren C, Xu K, Zhao K.
    J Immunother Cancer; 2024 Jun 25; 12(6):. PubMed ID: 38925679
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.